Gorobets O - Search Results

1

Twenty-five Years Overall Survival Prognostic Value of the Lymph Node Ratio in De Novo Metastatic Breast Cancer.

Gorobets O, Keam B, Vinh-Hung V, Nguyen NP. Gorobets O, et al. Anticancer Res. 2024 May;44(5):1995-2002. doi: 10.21873/anticanres.17002. Anticancer Res. 2024. PMID: 38677759

2

Breast cancer preoperative ¹⁸FDG-PET, overall survival prognostic separation compared with the lymph node ratio.

Vinh-Hung V, Everaert H, Gorobets O, Van Parijs H, Verfaillie G, Vanhoeij M, Storme G, Fontaine C, Lamote J, Perrin J, Farid K, Nguyen NP, Verschraegen C, De Ridder M. Vinh-Hung V, et al. Among authors: gorobets o. Breast Cancer. 2021 Jul;28(4):956-968. doi: 10.1007/s12282-021-01234-z. Epub 2021 Mar 10. Breast Cancer. 2021. PMID: 33689151

3

Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times.

Keam B, Gorobets O, Vinh-Hung V, Im SA. Keam B, et al. Among authors: gorobets o. Cancer Inform. 2021 Oct 12;20:11769351211051675. doi: 10.1177/11769351211051675. eCollection 2021. Cancer Inform. 2021. PMID: 34671180 Free PMC article.

4

Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer.

Vinh-Hung V, Van Parijs H, Gorobets O, Fontaine C, Nguyen NP, Keam B, Nguyen DM, De Ridder M. Vinh-Hung V, et al. Among authors: gorobets o. Sci Rep. 2022 Feb 22;12(1):2983. doi: 10.1038/s41598-022-07078-7. Sci Rep. 2022. PMID: 35194143 Free PMC article.

5

Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer.

Vinh-Hung V, Natchagande G, Joachim C, Gorobets O, Drame M, Bougas S, Folefac E, Nguyen NP, Verschraegen C, Yin M. Vinh-Hung V, et al. Among authors: gorobets o. Clin Genitourin Cancer. 2020 Dec;18(6):e660-e668. doi: 10.1016/j.clgc.2020.03.019. Epub 2020 Apr 7. Clin Genitourin Cancer. 2020. PMID: 32414694

6

Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.

Van Parijs H, Vinh-Hung V, Fontaine C, Storme G, Verschraegen C, Nguyen DM, Adriaenssens N, Nguyen NP, Gorobets O, De Ridder M. Van Parijs H, et al. Among authors: gorobets o. BMC Cancer. 2021 Nov 4;21(1):1177. doi: 10.1186/s12885-021-08916-z. BMC Cancer. 2021. PMID: 34736429 Free PMC article. Clinical Trial.

7

Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis.

Perrin J, Farid K, Van Parijs H, Gorobets O, Vinh-Hung V, Nguyen NP, Djassemi N, De Ridder M, Everaert H. Perrin J, et al. Among authors: gorobets o. World J Clin Oncol. 2022 Apr 24;13(4):287-302. doi: 10.5306/wjco.v13.i4.287. World J Clin Oncol. 2022. PMID: 35582655 Free PMC article.

8

Low-Dose Enzalutamide in Metastatic Prostate Cancer-Longevity Over Conventional Survival Analysis.

Vinh-Hung V, Gorobets O, Natchagande G, Sargos P, Yin M, Nguyen NP, Verschraegen C, Folefac E. Vinh-Hung V, et al. Among authors: gorobets o. Clin Genitourin Cancer. 2022 Dec;20(6):e473-e484. doi: 10.1016/j.clgc.2022.05.012. Epub 2022 Jun 6. Clin Genitourin Cancer. 2022. PMID: 35778336

9

Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer.

Van Parijs H, Cecilia-Joseph E, Gorobets O, Storme G, Adriaenssens N, Heyndrickx B, Verschraegen C, Nguyen NP, De Ridder M, Vinh-Hung V. Van Parijs H, et al. Among authors: gorobets o. Front Oncol. 2023 Nov 20;13:1211544. doi: 10.3389/fonc.2023.1211544. eCollection 2023. Front Oncol. 2023. PMID: 38053657 Free PMC article.

10

Two-Level Factorial Pre-TomoBreast Pilot Study of Tomotherapy and Conventional Radiotherapy in Breast Cancer: Post Hoc Utility of a Mean Absolute Dose Deviation Penalty Score.

Heymann S, Dipasquale G, Nguyen NP, San M, Gorobets O, Leduc N, Verellen D, Storme G, Van Parijs H, De Ridder M, Vinh-Hung V. Heymann S, et al. Among authors: gorobets o. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820947759. doi: 10.1177/1533033820947759. Technol Cancer Res Treat. 2020. PMID: 32940569 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page